Document › Details
4-Antibody AG. (3/16/10). "Press Release: 4-Antibody Announces Long-term Collaboration with Boehringer Ingelheim for Therapeutic Antibodies". Basel.
|Organisation 2||Boehringer Ingelheim (Group)|
|Product 2||MAb, human, fully|
|Index term||Boehringer–4-Antibody: therapeutic antibodies, 201003– collab up to €177.5m incl upfront + milestones discovery + developm fully human antibodies|
|Person||Grawunder, Ulf (4-Antibody 200810 CSO before CEO + founder)|
4-Antibody AG today announces a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. 4-Antibody will use its proprietary and unencumbered Hu-PAC® and Retrocyte Display® technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones. Further financial details were not disclosed.
Dr. Ulf Grawunder, co-founder and CSO of 4-Antibody AG, said “This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody’s fully human antibody discovery and engineering platforms to create valuable potential new drug candidates. Our unique and unencumbered technology capabilities allow the efficient generation of novel or improved fully human antibodies against any target class for our collaboration partners and for our own clinical development pipeline.”
- ends -
About 4-Antibody AG
4-Antibody AG is a privately held Swiss Biotech company active in the area of therapeutic
antibody drug development. 4-Antibody AG has developed a portfolio of powerful, proprietary
antibody discovery and engineering platforms, including the Hu-PAC® and the Retrocyte Display® technologies. 4-Antibody AG owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen of granted patents worldwide. The company has 40 employees working at its headquarter in Basel, Switzerland, and its subsidiary in Jena, Germany.
Record changed: 2016-03-20
More documents for Agenus (Group)
-  Agenus Inc.. (11/5/15). "Press Release: Agenus to Acquire Antibody Manufacturing Capability, Expands Antibody Discovery and Adds Cell Line Development Capabilities with Three Separate Transactions". Lexington, MA....
-  Incyte Corporation. (1/9/15). "Press Release: Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-oncology Antibodies". Wilmington, DE & Lexington, MA....
-  Agenus Inc.. (5/8/14). "Press Release: Agenus Reports First Quarter 2014 Financial Results". Lexington, MA....
-  Agenus Inc.. (4/28/14). "Press Release: Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-based Cancer Immunotherapies". Lexington, MA....
-  Agenus Inc.. (3/5/14). "Press Release: Agenus Reports Fourth Quarter and Full Year 2013 Financial Results". Lexington, MA....
-  Agenus Inc.. (2/13/14). "Press Release: Agenus Closes Acquisition of 4-Antibody". Lexington, MA....
-  Agenus Inc.. (2/10/14). "Press Release: Agenus Announces Closing of Public Offering and Exercise of Over-allotment Option". Lexington, MA....
-  Agenus Inc.. (1/13/14). "Press Release: Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG". Lexington, MA....
-  4-Antibody AG. (1/29/13). "Press Release: 4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets". Basel & New York, NY....
-  4-Antibody AG. (10/8/12). "Press Release: 4-Antibody AG Receives Additional Milestone Payments from Human Genome Sciences". Basel....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)